Use of Brentuximab Vedotin in a Non-HIV Patient with Primary Effusion Lymphoma.
Primary effusion lymphoma
brentuximab vedotin
non-HIV
Journal
European journal of case reports in internal medicine
ISSN: 2284-2594
Titre abrégé: Eur J Case Rep Intern Med
Pays: Italy
ID NLM: 101648453
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
02
2021
accepted:
02
02
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
27
3
2021
Statut:
epublish
Résumé
Primary effusion lymphoma is a rare and aggressive large B-cell lymphoma presenting as malignant effusion with poor prognosis. Although it is more prevalent among HIV patients, it has also been described in non-HIV immunocompromised individuals. Given its rarity, there are no large randomized trials regarding the best therapeutic option. The choice of therapy is based on retrospective studies, case reports and preclinical data. We present the case of a non-HIV patient with relapsed disease after treatment with CHOP who was then successfully treated with brentuximab vedotin, achieving complete remission. Primary effusion lymphoma is a rare entity in non-HIV patients, so there are no clinical trials regarding therapeutic options or management decisions.Targeted therapy with brentuximab vedotin has been used in other CD30 positive malignancies and in HIV-related primary effusion lymphoma with good outcomes.We present the case of a non-HIV patient with primary effusion lymphoma who was successfully treated with brentuximab vedotin, which highlights the potential role of a new therapeutic approach in this subgroup of patients.
Identifiants
pubmed: 33768081
doi: 10.12890/2021_002345
pii: 2345-1-20766-1-10-20210218
pmc: PMC7977055
doi:
Types de publication
Journal Article
Langues
eng
Pagination
002345Informations de copyright
© EFIM 2021.
Déclaration de conflit d'intérêts
Conflicts of Interests: The Authors declare that there are no competing interests.
Références
Blood. 2013 Aug 15;122(7):1233-42
pubmed: 23838350
Blood Adv. 2019 Mar 12;3(5):766-768
pubmed: 30837213
Intractable Rare Dis Res. 2014 Aug;3(3):65-74
pubmed: 25364646
Onco Targets Ther. 2018 Jun 28;11:3747-3754
pubmed: 29988764
Leuk Lymphoma. 2001 Apr;41(3-4):439-43
pubmed: 11378560